ABT the Leader and Winner--on to $80s in 2013 --Easy
The regimen with the highest SVR12 rates contained the Abbott experimental drugs--ABT-450 with ritonavir, ABT-267 and ABT-333--plus ribavirin for 12 weeks.
This regimen led to an SVR12 rate of 99% in 77 patients who hadn't received prior treatment, and 93% among 41 patients who hadn't responded well to therapy containing the injectable drug interferon.
Read more: http://www.foxbusiness.com/news/2012/10/15/abbott-hepatitis-c-regimen-suppresses-virus-in-new-study/#ixzz29cPMs1ua
Sentiment: Strong Buy